Trial · NCT05505734
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) | BDA MDI (PT027) 160/180 μg | 62 | Participants | ||
| Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) | AS MDI (PT007) 180 µg | 110 | Participants | ||
| Time to First Severe Asthma Exacerbation, Treatment Policy Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) | BDA MDI (PT027) 160/180 μg | 64 | Participants | ||
| Time to First Severe Asthma Exacerbation, Treatment Policy Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) | AS MDI (PT007) 180 µg | 114 | Participants | ||
| Time to First Severe Asthma Exacerbation, While on Treatment Strategy (Participants Aged >=18 Years) | BDA MDI (PT027) 160/180 μg | 71 | Participants | ||
| Time to First Severe Asthma Exacerbation, While on Treatment Strategy (Participants Aged >=18 Years) | AS MDI (PT007) 180 µg | 126 | Participants | ||
| Time to First Severe Asthma Exacerbation, Treatment Policy Strategy (Participants Aged >=18 Years) | BDA MDI (PT027) 160/180 μg | 73 | Participants | ||
| Time to First Severe Asthma Exacerbation, Treatment Policy Strategy (Participants Aged >=18 Years) | AS MDI (PT007) 180 µg | 131 | Participants | ||
| Annualized Severe Asthma Exacerbation Rate, While on Treatment Strategy (Participants Aged >=12 Years) | BDA MDI (PT027) 160/180 μg | 0.15 | 95% Confidence Interval 0.11 to 0.20 | events per year | |
| Annualized Severe Asthma Exacerbation Rate, While on Treatment Strategy (Participants Aged >=12 Years) | AS MDI (PT007) 180 µg | 0.32 | 95% Confidence Interval 0.25 to 0.41 | events per year | |
| Annualized Severe Asthma Exacerbation Rate, While on Treatment Strategy (Participants Aged >=18 Years) | BDA MDI (PT027) 160/180 μg | 0.15 | 95% Confidence Interval 0.12 to 0.20 | events per year | |
| Annualized Severe Asthma Exacerbation Rate, While on Treatment Strategy (Participants Aged >=18 Years) | AS MDI (PT007) 180 µg | 0.33 | 95% Confidence Interval 0.26 to 0.43 | events per year | |
| Total Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=12 Years) | BDA MDI (PT027) 160/180 μg | 23.2 | Full Range 0.0 to 2840.8 | mg/year | |
| Total Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=12 Years) | AS MDI (PT007) 180 µg | 61.9 | Full Range 0.0 to 21915.0 | mg/year | |
| Total Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=18 Years) | BDA MDI (PT027) 160/180 μg | 23.0 | Full Range 0.0 to 2840.8 | mg/year | |
| Total Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=18 Years) | AS MDI (PT007) 180 µg | 63.0 | Full Range 0.0 to 21915.0 | mg/year | |
| Total Duration of Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=12 Years) | BDA MDI (PT027) 160/180 μg | 0.4 | Standard Deviation 2.17 | days | |
| Total Duration of Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=12 Years) | AS MDI (PT007) 180 µg | 0.9 | Standard Deviation 3.66 | days | |
| Total Duration of Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=18 Years) | BDA MDI (PT027) 160/180 μg | 0.4 | Standard Deviation 2.20 | days | |
| Total Duration of Systemic Glucocorticoid Exposure, While on Treatment Strategy (Participants Aged >=18 Years) | AS MDI (PT007) 180 µg | 0.9 | Standard Deviation 3.72 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05505734/results